PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.

Area of Science:

• Oncology
• Immunotherapy
• Genetics

Background:

• Polybromo-1 (PBRM1) mutations are associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC).
• The correlation between PBRM1 mutations and immune checkpoint inhibitor (ICI) response in pan-cancer settings requires further clarification.

Purpose of the Study:

• To investigate the association between PBRM1 mutations and ICI efficacy in a pan-cancer cohort.
• To explore the relationship between PBRM1 and the tumor immune microenvironment.

Main Methods:

• Retrospective analysis of clinical and whole exome sequencing (WES) data from seven immunotherapy studies (discovery cohort).
• Validation using a separate large cohort and a non-small cell lung cancer (NSCLC) cohort.
• Gene set enrichment analysis (GSEA) to assess immune-related pathways.

Main Results:

• PBRM1 mutations correlated with improved progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) in the discovery cohort.
• PBRM1 mutations were associated with longer overall survival (OS) in the validation cohort.
• Significant improvements in PFS, ORR, and DCR were observed in NSCLC patients with PBRM1 mutations.
• GSEA revealed PBRM1 mutations are linked to immune efficacy, including T-cell activation and cytokine production.

Conclusions:

• PBRM1 mutations show a strong correlation with patient prognosis and immune response to immunotherapy.
• PBRM1 mutation status may serve as a predictive biomarker for guiding clinical management and personalized immunotherapy strategies.